The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 05, 1998
Filed:
Jun. 07, 1995
Mark H Skolnick, Salt Lake City, UT (US);
David E Goldgar, Salt Lake City, UT (US);
Yoshio Miki, Salt Lake City, UT (US);
Jeff Swenson, Salt Lake City, UT (US);
Alexander Kamb, Salt Lake City, UT (US);
Keith D Harshman, Salt Lake City, UT (US);
Donna M Shattuck-Eidens, Salt Lake City, UT (US);
Sean V Tavtigian, Salt Lake City, UT (US);
Roger W Wiseman, Durham, NC (US);
P Andrew Futreal, Durham, NC (US);
Myraid Genetics, Inc., Salt Lake City, UT (US);
University of Utah Research Foundation, Salt Lake City, UT (US);
The United States of America as represented by the Secretary of Health, , US;
Abstract
The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.